ANTABIO is dedicated to the discovery of novel drugs to treat and prevent antibiotic-resistant bacterial infections.
ANTABIO’s novel compounds block the virulence and the drug-resistance mechanisms of pathogenic bacteria by targeting key bacterial pathways.
Incorporated in 2009, the company is based in the life-sciences technopark “Prologue Biotech” in Labège, France.
ANTABIO welcomes M. Christophe RICARD former CEO of the Swiss pharmaceutical group OM Pharma as its new investor
Antabio is being recognized as a key player in the fight against drug-resistant bacteria.
Antabio appears in the last issues of 2 magazines.
Antabio will attend the French Biotech Tour in Boston from the 20 to 21 september 2011
What is the French Biotech Tour?
